Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Firuglipel is an orally available and selective agonist of GPR119.
Description | Firuglipel is an orally available and selective agonist of GPR119. |
In vitro | Firuglipel increases intracellular cAMP in a concentration-dependent manner in rat, human, and mouse GPR119-expressing Chinese hamster ovary (CHO)-K1 cells (EC50: 51.5, 98.4, and 108.1 nM, respectively). Firuglipel has no effect on intracellular cAMP in pcDNA3.1/CHO-K1 cells. |
In vivo | Firuglipel (1-30 mg/kg) upregulates glucagon-like peptide-1. It also enhances glucose-dependent insulin secretion and improves glucose homeostasis in type 2 diabetic rats. |
Molecular Weight | 467.49 |
Formula | C25H26FN3O5 |
CAS No. | 1371591-51-3 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Firuglipel 1371591-51-3 G蛋白偶联受体 内分泌与激素 GPR Inhibitor inhibitor inhibit